Goldmann-Favre Syndrome

Goldmann-Favre Syndrome is a very rare, inherited eye disease that affects the retina, the light-sensitive tissue at the back of the eye. It is caused by a genetic mutation that changes how the light-detecting cells in the eye develop. Normally, the eye has many "rod" cells for seeing in the dark and fewer "cone" cells for seeing colors. In this syndrome, the eye doesn't make working rod cells and instead makes too many of a specific type of cone cell that detects blue light. Because of this mix-up in cells, people with Goldmann-Favre Syndrome usually experience night blindness from a very young age. They may also notice that they are unusually sensitive to blue light. Over time, the condition causes progressive damage to the retina, leading to a gradual loss of central and side vision. Other eye problems, such as cataracts or fluid buildup in the center of the retina, can also occur and worsen vision. While there is currently no cure for Goldmann-Favre Syndrome, regular visits to an eye doctor are essential. Treatments like special eye drops or pills can sometimes help manage the fluid buildup in the retina, and surgery can remove cataracts if they develop. Genetic testing and counseling can help families understand the condition and how it is passed down.

Condition category: Retinal Dystrophy

Prevalence: Extremely rare

Inheritance patterns: Autosomal Recessive

Age of onset: Childhood to early adulthood

Clinical overview: Note: Goldmann-Favre Syndrome is the severe phenotypic presentation of Enhanced S-Cone Syndrome (ESCS). Both are caused by NR2E3 mutations. Goldmann-Favre represents the more severe end of the NR2E3-related retinopathy spectrum. See also the Enhanced S-Cone Syndrome entry. Goldmann-Favre Syndrome (GFS), also known as Enhanced S-Cone Syndrome (ESCS), is a rare, progressive, autosomal recessive vitreoretinal dystrophy. It is uniquely characterized by a gain of function in a specific type of photoreceptor—the S-cones (short-wavelength or blue cones)—coupled with a profound loss of rod photoreceptor function. This abnormal cellular composition results from a defect in photoreceptor cell fate determination during retinal development. Clinically, the syndrome presents with early-onset night blindness (nyctalopia), increased sensitivity to blue light, and progressive loss of visual acuity. Key ocular findings include vitreous degeneration (liquefaction and fibrillar strands), peripheral retinoschisis, cystoid macular edema, and characteristic nummular pigmentary changes in the retina. The condition is often complicated by the early development of cataracts. GFS is considered the severe end of the phenotypic spectrum of NR2E3-related retinopathies. The diagnosis is strongly supported by pathognomonic electroretinogram (ERG) findings, which show absent rod responses and hypersensitive S-cone responses. The condition is cataloged under OMIM #268100 (Enhanced S-Cone Syndrome) and OMIM *604485 (NR2E3 gene), and its Orphanet number is ORPHA:53540.

Patient and family guide: Goldmann-Favre Syndrome is a very rare, inherited eye disease that affects the retina, the light-sensitive tissue at the back of the eye. It is caused by a genetic mutation that changes how the light-detecting cells in the eye develop. Normally, the eye has many "rod" cells for seeing in the dark and fewer "cone" cells for seeing colors. In this syndrome, the eye doesn't make working rod cells and instead makes too many of a specific type of cone cell that detects blue light. Because of this mix-up in cells, people with Goldmann-Favre Syndrome usually experience night blindness from a very young age. They may also notice that they are unusually sensitive to blue light. Over time, the condition causes progressive damage to the retina, leading to a gradual loss of central and side vision. Other eye problems, such as cataracts or fluid buildup in the center of the retina, can also occur and worsen vision. While there is currently no cure for Goldmann-Favre Syndrome, regular visits to an eye doctor are essential. Treatments like special eye drops or pills can sometimes help manage the fluid buildup in the retina, and surgery can remove cataracts if they develop. Genetic testing and counseling can help families understand the condition and how it is passed down.

Symptoms and clinical features: In the early stages, typically during childhood, the most prominent symptom of Goldmann-Favre Syndrome is nyctalopia (night blindness). This occurs because the patients lack functional rod photoreceptors from birth. Children may also present with hypermetropia (farsightedness), decreased visual acuity, and an unusual increased sensitivity to blue light. Strabismus (such as accommodative esotropia) and nystagmus may also be observed in some early cases. During the intermediate stages, usually in adolescence to early adulthood, visual acuity progressively declines. Patients may begin to experience photopsia (flashes of light) and a constriction of their peripheral visual field. Clinical examination at this stage often reveals the characteristic nummular (coin-shaped) pigmentary changes along the vascular arcades, yellow-white subretinal lesions, and the development of macular schisis or cystoid macular edema, which further impairs central vision. In the advanced stages, the retinal degeneration becomes more pronounced. The macular schisis cavities can collapse, leading to significant macular atrophy and profound central vision loss. The peripheral visual field continues to constrict. Patients frequently develop early-onset posterior subcapsular cataracts, which compound the visual impairment. In some severe cases, complications such as choroidal neovascularization or retinal detachment may occur, leading to further sudden and severe vision loss.

Molecular pathology: Goldmann-Favre Syndrome is primarily caused by mutations in the NR2E3 gene, which encodes a photoreceptor-specific nuclear receptor. This protein functions as a critical transcription factor during retinal development. Normally, NR2E3 promotes the differentiation of rod photoreceptors while simultaneously repressing the expression of cone-specific genes, particularly those associated with S-cones (short-wavelength cones). When the NR2E3 protein is mutated and loses its normal function, the delicate balance of photoreceptor cell fate determination is disrupted. The progenitor cells that would normally develop into rods fail to do so, and instead, default to an S-cone default pathway. This results in a retina that is virtually devoid of functional rods and possesses an abnormally high number of S-cones. The altered cellular composition leads to the unique functional and structural abnormalities seen in the disease. The excess S-cones cause the characteristic hypersensitivity to blue light, while the lack of rods results in early-onset night blindness. Furthermore, the abnormal retinal architecture, including the presence of larger cells with an S-cone phenotype in place of rods, contributes to the progressive retinal degeneration, macular schisis, and vitreous changes characteristic of the syndrome.

Genetics: Goldmann-Favre Syndrome is inherited in an autosomal recessive manner. It is caused by biallelic mutations in the NR2E3 gene (Nuclear Receptor Subfamily 2 Group E Member 3), located on chromosome 15q23. The NR2E3 gene encodes a photoreceptor-specific orphan nuclear receptor that acts as a ligand-dependent transcription factor. It is crucial for the proper development and differentiation of rod photoreceptors and for the suppression of cone-specific genes in rods. Mutations in this gene lead to a failure of rod differentiation and an overproduction of S-cones (short-wavelength or blue cones). A common mutation associated with the condition is the R311Q missense mutation, which has been identified in numerous patients. The phenotypic expression of NR2E3 mutations can vary significantly, ranging from the severe Goldmann-Favre Syndrome to the milder Enhanced S-Cone Syndrome (ESCS), and even some forms of autosomal dominant and recessive retinitis pigmentosa. This genetic heterogeneity highlights the complex role of NR2E3 in retinal development.

Diagnostic evaluation: Diagnosis of Goldmann-Favre Syndrome (GFS) relies on a combination of clinical evaluation, multimodal imaging, and electrophysiological testing. Fundoscopy typically reveals peripheral pigmentary changes (often nummular or clumped, rather than the bone spicules seen in retinitis pigmentosa), a yellowish foveal reflex, and vitreous changes such as liquefaction or fibrillar strands. Macular schisis and cystoid macular edema are also common findings. Optical coherence tomography (OCT) is critical for identifying foveoschisis, demonstrating pronounced intraretinal schisis cavities, particularly involving the inner nuclear and outer plexiform layers. Fundus autofluorescence (FAF) often shows a speckled pattern of hyperautofluorescence in the central macula with patchy hypoautofluorescent zones along the vascular arcades, lacking the typical hyperautofluorescent ring seen in retinitis pigmentosa. Electroretinography (ERG) is pathognomonic, showing absent rod responses and abnormal cone responses dominated by S-cone mechanisms. The 30 Hz flicker response is typically delayed and of low amplitude. A specific S-cone ERG protocol (blue stimulus on an orange background) elicits a larger-than-normal response. Genetic testing confirming biallelic mutations in the NR2E3 gene definitively establishes the diagnosis. Differential diagnosis includes X-linked retinoschisis, retinitis pigmentosa, and Wagner disease.

Differential diagnosis: Differential diagnosis of Goldmann-Favre syndrome includes: (1) Enhanced S-cone syndrome — same genetic basis (NR2E3), less prominent vitreous/schisis changes. (2) X-linked retinoschisis — macular schisis, RS1 mutations, no enhanced S-cone response. (3) Wagner syndrome — vitreous degeneration, VCAN mutations, no enhanced S-cone. (4) Retinitis pigmentosa with CME — cystoid macular edema can mimic schisis. (5) Juvenile retinoschisis — similar age of onset, different ERG pattern.

Natural history: Goldmann-Favre Syndrome is a progressive vitreoretinal dystrophy. The onset of symptoms typically occurs in childhood or early adolescence, with night blindness (nyctalopia) often being the first noticeable sign due to the congenital absence of functional rod photoreceptors. As the disease progresses into the second and third decades of life, patients experience a gradual decline in visual acuity and constriction of the visual field. The development of macular schisis and cystoid macular edema can significantly impact central vision. The rate of progression is highly variable among affected individuals, even those with the same genetic mutation. While some patients may maintain relatively good vision for many years, others may experience severe visual impairment by early adulthood. Complications such as early-onset cataracts and, less commonly, choroidal neovascularization or retinal detachment, can further accelerate visual loss.

Management and treatment research: ### Current Management There is currently no cure for Goldmann-Favre syndrome (GFS), an inherited retinal disease most often associated with changes in the **NR2E3** gene. Care focuses on preserving remaining vision, monitoring retinal changes, and treating complications that can further affect sight. - **Regular retinal follow-up:** Eye examinations, retinal imaging, visual-field testing, and optical coherence tomography (OCT)—a scan that shows retinal layers and fluid—can monitor retinal degeneration, macular schisis (splitting of retinal layers), and cystoid macular edema (fluid-related swelling in the central retina). - **Treatment for retinal fluid:** Carbonic anhydrase inhibitors, including topical **dorzolamide** eye drops or oral **acetazolamide**, may be used for macular schisis or cystoid macular edema. These medicines can reduce retinal fluid for some people, although improvement and how long it lasts vary. - **Cataract care:** Posterior subcapsular cataracts may occur. Cataract surgery may be considered when a cataract significantly affects vision or daily activities. - **Management of complications:** Rare complications such as choroidal neovascularization—abnormal blood vessel growth beneath the retina—may be treated with anti-VEGF injections into the eye. Symptoms that may suggest retinal detachment, vitreous hemorrhage, or another urgent retinal problem should be assessed promptly by a vitreoretinal specialist. - **Genetic testing and counseling:** Genetic testing can help confirm the diagnosis, identify the responsible gene change, inform family counseling, and determine possible eligibility for registries or research studies. Because GFS may overlap clinically with other NR2E3-related retinal conditions, an inherited retinal disease specialist can help interpret results. ### Approved Therapies There are no therapies specifically approved for Goldmann-Favre syndrome or for **NR2E3**-related retinal disease. ### Investigational Therapies There are no treatment candidates listed specifically for Goldmann-Favre syndrome in the current treatment pipeline. #### Gene Therapy Research One ongoing study is evaluating **OCU400**, an investigational gene therapy intended to deliver a functional copy of the **NR2E3** gene: - **NCT05203939** — *Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis* (Phase 1/2; active, not recruiting) This trial is for retinitis pigmentosa and Leber congenital amaurosis, not specifically for Goldmann-Favre syndrome. “Active, not recruiting” means the study is continuing but is not currently enrolling new participants. If future enrollment or related studies become available, eligibility would depend on factors such as the person’s genetic result, retinal findings, vision level, and the study’s inclusion criteria. ### Clinical Trial Participation Research opportunities for rare inherited retinal diseases can change over time. Natural-history and registry studies help researchers understand how conditions progress and may support future research. - **NCT02435940** — *Inherited Retinal Degenerative Disease Registry* (recruiting) People with Goldmann-Favre syndrome can discuss genetic testing, registry participation, and research opportunities with an inherited retinal disease specialist.

Outlook: The prognosis for Goldmann-Favre Syndrome involves a progressive decline in visual function, though the severity and rate of progression vary significantly among individuals. Most patients experience significant visual loss by their second or third decade of life, primarily due to macular schisis, progressive retinal degeneration, and the development of cataracts. Quality of life is impacted by the early onset of night blindness and the gradual loss of visual acuity and visual fields. However, patients are not typically completely blind, even in older age. Regular monitoring and supportive treatments, such as managing macular edema and performing cataract surgery when necessary, can help maximize and preserve remaining vision for as long as possible.

Epidemiology: Goldmann-Favre Syndrome is an extremely rare condition, with an estimated prevalence of less than 1 in 1,000,000 individuals worldwide. Fewer than 100 cases have been reported in the medical literature. The condition affects both males and females equally. It is often observed in populations with high rates of consanguinity, as it follows an autosomal recessive inheritance pattern. Geographic clusters have been noted in certain endogamous populations, such as Crypto-Jews in Portugal, but it can occur in any ethnic group.

Selected references: 1. Haider NB, et al. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet. 2000. PMID: 10655056 2. Jacobson SG, et al. Nuclear receptor NR2E3 gene mutations distort human retinal laminar architecture and cause an unusual degeneration. Hum Mol Genet. 2004. PMID: 15229190 3. de Carvalho ER, et al. Enhanced S-cone syndrome: spectrum of clinical, imaging, electrophysiological and genetic findings in a retrospective case series of 56 patients. Ophthalmol Retina. 2021. PMID: 32679203 4. Yzer S, et al. Expanded clinical spectrum of enhanced S-cone syndrome. JAMA Ophthalmol. 2013. PMID: 23928951 5. Bernal S, et al. Analysis of the involvement of the NR2E3 gene in autosomal recessive retinal dystrophies. Clin Genet. 2008. PMID: 18294254 6. Tsang SH, Sharma T. Enhanced S-Cone Syndrome (Goldmann-Favre Syndrome). Adv Exp Med Biol. 2018. PMID: 30578501